Zoetis Inc. $ZTS Shares Bought by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its stake in Zoetis Inc. (NYSE:ZTS) by 7.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 46,755 shares of the company’s stock after buying an additional 3,443 shares during the quarter. Achmea Investment Management B.V.’s holdings in Zoetis were worth $7,292,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Lindbrook Capital LLC boosted its stake in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after buying an additional 65 shares in the last quarter. Scott & Selber Inc. grew its holdings in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares in the last quarter. Secure Asset Management LLC raised its stake in shares of Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares in the last quarter. Quotient Wealth Partners LLC lifted its stake in Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after acquiring an additional 72 shares during the last quarter. Finally, Moment Partners LLC boosted its holdings in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $119.81 on Friday. The firm’s 50 day moving average is $144.93 and its 200-day moving average is $152.78. Zoetis Inc. has a 12-month low of $119.06 and a 12-month high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $53.10 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the business earned $1.58 EPS. Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday. Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $191.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.